Literature DB >> 12019079

Resistance mechanisms in clinical isolates of Candida albicans.

Theodore C White1, Scott Holleman, Francis Dy, Laurence F Mirels, David A Stevens.   

Abstract

Resistance to azole antifungals continues to be a significant problem in the common fungal pathogen Candida albicans. Many of the molecular mechanisms of resistance have been defined with matched sets of susceptible and resistant clinical isolates from the same strain. Mechanisms that have been identified include alterations in the gene encoding the target enzyme ERG11 or overexpression of efflux pump genes including CDR1, CDR2, and MDR1. In the present study, a collection of unmatched clinical isolates of C. albicans was analyzed for the known molecular mechanisms of resistance by standard methods. The collection was assembled so that approximately half of the isolates were resistant to azole drugs. Extensive cross-resistance was observed for fluconazole, clotrimazole, itraconazole, and ketoconazole. Northern blotting analyses indicated that overexpression of CDR1 and CDR2 correlates with resistance, suggesting that the two genes may be coregulated. MDR1 overexpression was observed infrequently in some resistant isolates. Overexpression of FLU1, an efflux pump gene related to MDR1, did not correlate with resistance, nor did overexpression of ERG11. Limited analysis of the ERG11 gene sequence identified several point mutations in resistant isolates; these mutations have been described previously. Two of the most common point mutations in ERG11 associated with resistance, D116E and E266D, were tested by restriction fragment length polymorphism analysis of the isolates from this collection. The results indicated that the two mutations occur frequently in different isolates of C. albicans and are not reliably associated with resistance. These analyses emphasize the diversity of mechanisms that result in a phenotype of azole resistance. They suggest that the resistance mechanisms identified in matched sets of susceptible and resistant isolates are not sufficient to explain resistance in a collection of unmatched clinical isolates and that additional mechanisms have yet to be discovered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019079      PMCID: PMC127245          DOI: 10.1128/AAC.46.6.1704-1713.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Transcriptional analyses of antifungal drug resistance in Candida albicans.

Authors:  C N Lyons; T C White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  Sequence of the Candida albicans gene encoding actin.

Authors:  C Losberger; J F Ernst
Journal:  Nucleic Acids Res       Date:  1989-11-25       Impact factor: 16.971

3.  Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans.

Authors:  M H Lai; D R Kirsch
Journal:  Nucleic Acids Res       Date:  1989-01-25       Impact factor: 16.971

4.  Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations.

Authors:  R Pelletier; J Peter; C Antin; C Gonzalez; L Wood; T J Walsh
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans.

Authors:  Patrick Marichal; Luc Koymans; Staf Willemsens; Danny Bellens; Peter Verhasselt; Walter Luyten; Marcel Borgers; Frans C S Ramaekers; Frank C Odds; Hugo Vanden Bossche
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

6.  Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors:  S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Mitotic recombination in Candida albicans: recessive lethal alleles linked to a gene required for methionine biosynthesis.

Authors:  W L Whelan; D R Soll
Journal:  Mol Gen Genet       Date:  1982

8.  Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans.

Authors:  V Perepnikhatka; F J Fischer; M Niimi; R A Baker; R D Cannon; Y K Wang; F Sherman; E Rustchenko
Journal:  J Bacteriol       Date:  1999-07       Impact factor: 3.490

9.  A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli.

Authors:  C S Hoffman; F Winston
Journal:  Gene       Date:  1987       Impact factor: 3.688

10.  A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole.

Authors:  D Calabrese; J Bille; D Sanglard
Journal:  Microbiology       Date:  2000-11       Impact factor: 2.777

View more
  136 in total

1.  An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans.

Authors:  Samantha J Hoot; Adam R Smith; Ryan P Brown; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates.

Authors:  Somanon Bhattacharya; Jack D Sobel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Regulatory Role of ERG3 and Efg1 in Azoles-Resistant Strains of Candida albicans Isolated from Patients Diagnosed with Vulvovaginal Candidiasis.

Authors:  Wenli Feng; Jing Yang; Zhiqin Xi; Ying Ji; Xin Zhu; Lu Yang; Yan Ma
Journal:  Indian J Microbiol       Date:  2019-11-02       Impact factor: 2.461

4.  Synthesis and chain-dependent antifungal activity of long-chain 2H-azirine-carboxylate esters related to dysidazirine.

Authors:  Colin K Skepper; Doralyn S Dalisay; Tadeusz F Molinski
Journal:  Bioorg Med Chem Lett       Date:  2010-02-01       Impact factor: 2.823

5.  In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.

Authors:  Ana Carolina Azevedo; Fernando César Bizerra; Daniel Arquimedes da Matta; Leila Paula de Almeida; Robert Rosas; Arnaldo Lopes Colombo
Journal:  Mycopathologia       Date:  2010-12-23       Impact factor: 2.574

6.  In vitro effect of malachite green on Candida albicans involves multiple pathways and transcriptional regulators UPC2 and STP2.

Authors:  Sanjiveeni Dhamgaye; Frederic Devaux; Raman Manoharlal; Patrick Vandeputte; Abdul Haseeb Shah; Ashutosh Singh; Corinne Blugeon; Dominique Sanglard; Rajendra Prasad
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

7.  Inhibition of efflux transporter-mediated fungicide resistance in Pyrenophora tritici-repentis by a derivative of 4'-hydroxyflavone and enhancement of fungicide activity.

Authors:  Sven Reimann; Holger B Deising
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

8.  Multidrug-resistant transporter mdr1p-mediated uptake of a novel antifungal compound.

Authors:  Nuo Sun; Dongmei Li; William Fonzi; Xin Li; Lixin Zhang; Richard Calderone
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.